Does Illumina's (ILMN) Raised 2025 Outlook Reinforce Confidence in Its Long-Term Growth Story?

• In October 2025, Illumina announced higher full-year 2025 earnings guidance, projecting revenue between US$4.27 billion and US$4.31 billion, alongside its third quarter earnings report showing US$1,084 million in revenue, US$150 million in net income, and ongoing share repurchases.
• While net income for the third quarter fell significantly year-over-year, Illumina returned to profitability over the nine-month period and continued to buy back shares under its repurchase program.
• We'll examine how Illumina's raised 2025 revenue guidance and financial updates impact its long-term investment narrative.

Find companies with promising cash flow potential yet trading below their fair value.

Illumina Investment Narrative Recap

To be a shareholder in Illumina, you need confidence in the expanding use of genomic sequencing in clinical settings and the company’s ability to keep innovating while defending market share. The recent, modest raise in 2025 revenue guidance following flat third-quarter revenue provides short-term reassurance on performance, but it does not meaningfully change the most important catalyst, clinical market growth, or the key risk, which remains pressure from intensifying competition and pricing.

Among Illumina’s latest developments, the company’s ongoing share repurchase program stands out. Completing US$120 million in recent buybacks and nearly US$942 million since late 2024 reflects a commitment to returning capital to shareholders. This move comes even as margin pressures and competition persist, tying directly back to short-term catalysts around earnings growth and longer-term confidence in the company’s product pipeline and profitability.

In contrast, investors should still be aware that competitive threats could impact Illumina more than recent guidance changes may suggest, particularly if...

Read the full narrative on Illumina (it's free!)

Illumina's narrative projects $4.8 billion revenue and $873.5 million earnings by 2028. This requires 3.6% yearly revenue growth and a $426.5 million earnings decrease from $1.3 billion today.

Uncover how Illumina's forecasts yield a $113.58 fair value, a 8% downside to its current price.

Exploring Other Perspectives

Five members of the Simply Wall St Community estimate Illumina’s fair value between US$86.26 and US$167.53 per share. While views are diverse, ongoing risks from competitors entering clinical sequencing markets could weigh on performance, highlighting a broad spectrum of possible outcomes that you should consider.

Explore 5 other fair value estimates on Illumina - why the stock might be worth 30% less than the current price!

Build Your Own Illumina Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Illumina research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Illumina research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Illumina's overall financial health at a glance.

Curious About Other Options?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• Uncover the next big thing with financially sound penny stocks that balance risk and reward.
• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com